News
Archive
Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735
Cambridge Epigenetix names Peter Fromen as Chief Executive Officer
Phase Four and Impulse Space to collaborate on multi-mode propulsion
Vascular Therapies completes $25 million private financing
Introducing Avari Wireless, a state-of-the-art designer & manufacturer of public safety DAS
Paragraf raises $60 million in Series B financing
Back To News

September 28, 2017
Juventas
Focused on the development of a non-viral gene therapy for advanced peripheral artery disease.